The former recently bought out Ranbaxy in a $4-billion deal.
Currently, Ranbaxy owns 46.84 per cent stake in Zenotech, while its parent Japan's Daiichi Sankyo holds 20 per cent.
A mandatory open offer for Zenotech has been triggered following the Sun-Ranbaxy deal. If it acquires the 28.1 per cent stake, Sun would own around 74.9 per cent of Zenotech.
Zenotech's former promoters, led by Jayaram Chigurupati, own 24.9 per cent of the company. On Friday, Zenotech shares were up 4.9 per cent at Rs 22.20 on the BSE.
Up to 9.6 million shares of face value of Rs 10 each of Zenotech, constituting 28.1 per cent (at Rs 19 an offer share aggregating to Rs 18.4 crore), can be bought by Sun, according to the latter.
Sun Pharma has all the reasons to cheer Ranbaxy deal
Dilip Shanghvi: Billionaire with Midas touch
Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US
Sun chief hopes the worst is over for Ranbaxy
Markets slip on global cues; IIP data eyed